Human serum albumin labeled with technetium-99m was encapsulated together with mag netite particles into phosphatidylcholine/cholesterol liposomes. In order to investigate the stability of this complex and its ability to be used for magnetic drug targeting, the in-vivo distribution after intravenous administration in rats was estimated. For in-vivo targeting an SmCo permanent magnet with intensity -0 .3 5 T was attached near the right kidney. Differ ence between the relative radioactivity in the magnetically targeted right kidney (25.92±5.84% ) and non-targeted left kidney (0.93±0.05% ) is sufficiently high for relevant clinical applications.
Introduction
One of the major challenges in cancer treatment is the delivery of anti-neoplastic agents to remote, difficult-to-reach anatomic sites. The aim of the specific cell targeting is to enhance efficiency of drug delivery and at the same time to reduce the toxicity and side effects to normal tissues. A l though many attempts have been made to find a clinically applicable way the problem is still not fully clarified. Conjugation of drugs to antibodies specific to target cell antigens is one example that is clinically being explored (Siegall, 1994 ). An other example is magnetic targeting based on mag netic pharmaceuticals (e.g. magnetic albumin and polymer microspheres) targeted after injection to the tumor region using external magnetic field. Increase of the therapeutic index of associated drugs using magnetic carriers is up to 1 0 0 -fold (Schütt et al., 1997) and has been shown by no other drug-targeting device.
Blood vessels in tumors are often leaky and have a higher permeability to circulate large mole cules up to sizes of 400 nm in diameter (Brown and Giaccia, 1998) . For a long time this property was used for delivery of drugs in liposomes (Lasic, 1998 Higher therapeutic doses of anti-cancer drugs are often toxic also for the normal cells, therefore even a slightly modified drug distribution (more of the drug delivered to the tumor) may results in a beneficial effects. One of the most important characteristics of an ideal targetable drug delivery system is its ability to traverse the endothelium of the targeted tissue and to release the encapsulated drug at the cellular level.
The objective of this study was to investigate the distribution, stability and specificity of magnetoli posomes (MLs) in rats. The targeting of intrave-nously injected 99mTc labeled MLs was provided by an external magnetic field applied near the right kidney.
The kidney was chosen as a target organ to open an avenue to treat renal tumors, which represent seventh leading cause of cancer and ome renal tu mors, e.g. rhabdoid kidney tumor are extremely aggressive and their therapy remains inadequate (Figlin 1999 . Therefore delivering and confining chemotherapeutic agent to kidney could be effec tive for treatment of these malignancies. 
Materials and Methods

Preparation
In vivo magnetoliposom e targeting
Adult female Sprague Dawley rats 200 g of weight were used throughout the experiments. For each experimental group two animals were used. 1 ml of 99m Tc-HSA-MLs were injected intrave nously into the rat tail. To study magnetoliposome distribution the two rats each were sacrified by de capitation at 20, 40, 60, 80, 100 and 120 minutes after injection. The blood was taken from heart, the lung, liver, spleen, heart, left and right kidney were immediately removed, blotted, weighted, and carefully minced. The 99mTc radioactivity of ali quots from obtained tissues was measured using a Clini Gamma Counter (LKB). The amounts of radioactivity retained in all tissue samples were measured and divided by the total activity admin istered (approximately 2.5 MBq in each rat) to ob tain the percentage distribution of the 99mTc in ev ery tissue. These percentages were then normalised with individual tissue sample weight to compensate for animal-to-animal variations. As a result the amount of radioactivity detected in the tissues represents the amounts of intact MLs taken from the blood-stream. Effects of magnetic field on MLs biodistribution were followed after attach ment of 1.5x1.5x2 cm SmCo magnet (surface mag netic intensity -0.35 T) close to the right kidney. During magnetic targeting the rats were anaesthe tized by i.p. administration of 0 .1 mg/kg atropine, 10 mg/kg Rometar (Xylzainum) and 90 mg/kg Narkamon (Ketaminum hydrochloridum) (all ob tained from Spofa a.s., Prague, Czech Republic), this step is not necessary but allows to achieve fixed experimental conditions during the study.
Results and Discussion
Intravenous administration of a magnetically re sponsive liposomes results in retention of this car riers in the blood vessels of the target tissue when an extracorporeal magnetic field is applied. The greater the carrier uptake, the lesser would be its availability at non-targeted sites.
As is known (Scherphof et al., 1978) , liposomes become permeable or destabilised in the presence of blood (allowing entrapped solutes to leak out) because plasma high density lipoproteins remove phospholipid molecules from the vesicle bilayer. In order to stabilise liposomes we have prepared them from a mixture of phosphatidylcholine/cho-lesterol. Using a 1 hr centrifugation at 12,000 xg obtained MLs were separated from non-encapsulated magnetite particles and HSA. Comparing the 99mTc radioactivity in supernatant and pellet a 49% efficiency of 99mTc-HSA encapsulation has been found. In the physiological saline buffer these MLs remain stable and retain the encapsu lated 99mTc for at least 12 hrs.
The kinetics of in vivo MLs distribution are summarised in Table I where Vmagnetite is the total volume of magnetite encapsulated in the MLs, x is the magnetic suscep tibility, H the strength of magnetic field and (dHI 9x) the magnetic field gradient. It is clear that the magnetic responsiveness of MLs is determined by many factors including strength of the applied magnetic field and physical properties of encapsu lated magnetic nanoparticles.
In related studies (Babincovä and Babinec, 1997; Viroonchatapan et al., 1995) it was shown that ML-encapsulated drugs may be released in response to electromagnetically induced heating of magnetic particles. Therefore our future studies should be directed to the investigation of cancer treatment using both magnetic guidance and electromagnetic drug release.
In conclusion, the obtained results demonstrate the usefulness of MLs for in-vivo targeting. The therapeutic benefit of such system will be further investigated by the application of doxorubicincontaining MLs in the treatment of rat sarcomas.
